Tevogen (TVGN) Total Liabilities (2021 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Total Liabilities came in at $14.8 million in Q1 2026, up 25.18% YoY from $11.8 million in Q1 2025, and up 17.0% on a QoQ basis from $12.6 million in Q4 2025.
Tevogen (TVGN) Total Liabilities (2021 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 6 years of Total Liabilities data on file, last reported at $14.8 million in Q1 2026.
- Quarterly Total Liabilities rose 25.18% year-over-year to $14.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.8 million (up 25.18% YoY) and the FY2025 annual result came in at $12.6 million, up 24.49% from the prior year.
- Total Liabilities climbed to $14.8 million in Q1 2026, from $12.6 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $99.9 million in Q4 2023 to a low of $9.2 million in Q1 2024.
- A 5-year average of $18.5 million and a median of $14.8 million in 2026 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2023 — Total Liabilities soared 563.68% — and 2024, when it plunged 89.86%.
- Tracing TVGN's Total Liabilities over 5 years: stood at $15.1 million in 2022, then soared by 563.68% to $99.9 million in 2023, then sank by 89.86% to $10.1 million in 2024, then rose by 24.49% to $12.6 million in 2025, then climbed by 17.0% to $14.8 million in 2026.
- The last three Total Liabilities figures came in at $14.8 million (Q1 2026), $12.6 million (Q4 2025), and $12.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 10.03 Bn |
| 10 | Tevogen | 25.73 Mn | 25.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.76 Mn |
| Dec 31, 2025 | 12.62 Mn |
| Sep 30, 2025 | 12.32 Mn |
| Jun 30, 2025 | 13.75 Mn |
| Mar 31, 2025 | 11.79 Mn |
| Dec 31, 2024 | 10.14 Mn |
| Sep 30, 2024 | 10.48 Mn |
| Jun 30, 2024 | 10.94 Mn |
| Mar 31, 2024 | 9.17 Mn |
| Dec 31, 2023 | 99.93 Mn |
| Sep 30, 2023 | 16.56 Mn |
| Jun 30, 2023 | 16.25 Mn |
| Mar 31, 2023 | 15.43 Mn |
| Dec 31, 2022 | 15.06 Mn |
| Sep 30, 2022 | 15.08 Mn |
| Jun 30, 2022 | 15.13 Mn |
| Mar 31, 2022 | 15.18 Mn |
| Dec 31, 2021 | 15.18 Mn |